Skip to main content

Advertisement

SpringerLink
Log in

Assessment of the treatment response of HCC

  • Invited Feature Section
  • Published:
Abdominal Imaging Aims and scope Submit manuscript

Abstract

Surgical hepatectomy or liver transplantation are considered as curative treatment modalities for hepatocellular carcinoma (HCC). However, many patients are not surgical candidates at the time of diagnosis. Great improvements in locoregional therapies including local ablative therapy [radiofrequency (RF) ablation or ethanol ablation] and transarterial techniques (transarterial embolization or transarterial radioembolization) have made possible local control of HCC. For unresectable HCC, a targeted therapy with sorafenib may improve survival. Unlike treatment of other oncologic tumor, the locoregional therapies are mainstay in the treatment of HCC. Therefore, the application of classical criteria such as the World Health Organization (WHO) guideline may not be suitable for accurate treatment response assessment of locoregional therapies or targeted therapy of HCC. An understanding of the imaging features of post-treatment imaging after various treatment modalities for HCC is crucial for treatment response assessment and for determining further therapy. In this article, we review the role of various imaging modalities in assessing treatment response of locoregional therapies and the targeted molecular therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12

Similar content being viewed by others

References

  1. Lau WY, Lai EC (2008) Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 7:237–257

    PubMed  Google Scholar 

  2. Sauer P, Kraus TW, Schemmer P, et al. (2005) Liver transplantation for hepatocellular carcinoma: is there evidence for expanding the selection criteria? Transplantation 80:S105–S108

    Article  PubMed  Google Scholar 

  3. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G (2009) Current management strategy of hepatocellular carcinoma. World J Gastroenterol 15:3210–3216

    Article  PubMed  CAS  Google Scholar 

  4. Lau WY (1997) The history of liver surgery. J R Coll Surg Edinb 42:303–309

    PubMed  CAS  Google Scholar 

  5. Zhang T, Ding X, Wei D, et al. (2010) Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs 21:326–332

    Article  PubMed  CAS  Google Scholar 

  6. World Health Organization (WHO) (1979) WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: WHO. WHO Offset Publication No. 48

  7. Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  8. Eisenhauer EA, Therasse P, Bogaerts J, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  PubMed  CAS  Google Scholar 

  9. Riaz A, Miller FH, Kulik LM, et al. (2010) Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 303:1062–1069

    Article  PubMed  CAS  Google Scholar 

  10. Forner A, Ayuso C, Varela M, et al. (2009) Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115:616–623

    Article  PubMed  Google Scholar 

  11. Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430

    Article  PubMed  CAS  Google Scholar 

  12. Harry VN, Semple SI, Parkin DE, Gilbert FJ (2010) Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol 11:92–102

    Article  PubMed  Google Scholar 

  13. Vossen JA, Buijs M, Kamel IR (2006) Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol 9:125–132

    Article  PubMed  Google Scholar 

  14. Yu JS, Kim JH, Chung JJ, Kim KW (2009) Added value of diffusion-weighted imaging in the MRI assessment of perilesional tumor recurrence after chemoembolization of hepatocellular carcinomas. J Magn Reson Imaging 30:153–160

    Article  PubMed  Google Scholar 

  15. Youn BJ, Chung JW, Son KR, et al. (2008) Diffusion-weighted MR: therapeutic evaluation after chemoembolization of VX-2 carcinoma implanted in rabbit liver. Acad Radiol 15:593–600

    Article  PubMed  Google Scholar 

  16. Chen G, Ma DQ, He W, Zhang BF, Zhao LQ (2008) Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 14:5738–5743

    Article  PubMed  Google Scholar 

  17. Jackson A, Haroon H, Zhu XP, et al. (2002) Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model. NMR Biomed 15:164–173

    Article  PubMed  CAS  Google Scholar 

  18. Kim KW, Lee JM, Klotz E, et al. (2009) Quantitative CT color mapping of the arterial enhancement fraction of the liver to detect hepatocellular carcinoma. Radiology 250:425–434

    Article  PubMed  Google Scholar 

  19. Choi BI, Lee JM (2009) Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments: imaging diagnosis and staging of hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 17:369–373

    Article  PubMed  Google Scholar 

  20. Sun HY, Lee JM, Shin CI, et al. (2010) Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or = 2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 45:96–103

    Article  PubMed  CAS  Google Scholar 

  21. Llovet JM, Real MI, Montana X, et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739

    Article  PubMed  Google Scholar 

  22. Lo CM, Ngan H, Tso WK, et al. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171

    Article  PubMed  CAS  Google Scholar 

  23. Lee HS, Kim KM, Yoon JH, et al. (2002) Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol 20:4459–4465

    Article  PubMed  Google Scholar 

  24. Riaz A, Lewandowski RJ, Kulik L, et al. (2010) Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol 33:1143–1152

    Article  PubMed  Google Scholar 

  25. Jang KM, Choi D, Lim HK, et al. (2005) Depiction of viable tumor in hepatocellular carcinoma treated with transarterial chemoembolization: multiphasic helical CT with review of the previous serial CT images. Korean J Radiol 6:153–160

    Article  PubMed  Google Scholar 

  26. Kamel IR, Bluemke DA, Eng J, et al. (2006) The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 17:505–512

    Article  PubMed  Google Scholar 

  27. Schima W, Ba-Ssalamah A, Kurtaran A, Schindl M, Gruenberger T (2007) Post-treatment imaging of liver tumours. Cancer Imaging 7 Spec No A:S28–S36

    Google Scholar 

  28. Kamel IR, Bluemke DA, Ramsey D, et al. (2003) Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 181:708–710

    PubMed  Google Scholar 

  29. Goshima S, Kanematsu M, Kondo H, et al. (2008) Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator? J Magn Reson Imaging 27:834–839

    Article  PubMed  Google Scholar 

  30. Ibrahim SM, Nikolaidis P, Miller FH, et al. (2009) Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging 34:566–581

    Article  PubMed  Google Scholar 

  31. Gates VL, Atassi B, Lewandowski RJ, et al. (2007) Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors. Future Oncol 3:73–81

    Article  PubMed  CAS  Google Scholar 

  32. Atassi B, Bangash AK, Bahrani A, et al. (2008) Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics 28:81–99

    Article  PubMed  Google Scholar 

  33. Duke E, Deng J, Ibrahim SM, et al. (2010) Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization. J Vasc Interv Radiol 21:515–521

    Article  PubMed  Google Scholar 

  34. Salem R, Lewandowski RJ, Mulcahy MF, et al. (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138:52–64

    Article  PubMed  CAS  Google Scholar 

  35. Rhee TK, Naik NK, Deng J, et al. (2008) Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 19:1180–1186

    Article  PubMed  Google Scholar 

  36. Gervais DA, Kalva S, Thabet A (2009) Percutaneous image-guided therapy of intra-abdominal malignancy: imaging evaluation of treatment response. Abdom Imaging 34:593–609

    Article  PubMed  Google Scholar 

  37. Rhim H, Goldberg SN, Dodd GD III, et al. (2001) Essential techniques for successful radio-frequency thermal ablation of malignant hepatic tumors. Radiographics 21 Spec No:S17–S35; discussion S36–S19

  38. Goldberg SN, Gazelle GS, Compton CC, Mueller PR, Tanabe KK (2000) Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer 88:2452–2463

    Article  PubMed  CAS  Google Scholar 

  39. Lim HK, Choi D, Lee WJ, et al. (2001) Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology 221:447–454

    Article  PubMed  CAS  Google Scholar 

  40. Dromain C, de Baere T, Elias D, et al. (2002) Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology 223:255–262

    Article  PubMed  Google Scholar 

  41. Goldberg SN, Grassi CJ, Cardella JF, et al. (2009) Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol 20:S377–S390

    Article  PubMed  Google Scholar 

  42. Park MH, Rhim H, Kim YS, et al. (2008) Spectrum of CT findings after radiofrequency ablation of hepatic tumors. Radiographics 28:379–390; discussion 390–372

    Article  PubMed  Google Scholar 

  43. Ozkavukcu E, Haliloglu N, Erden A (2009) Post-treatment MRI findings of hepatocellular carcinoma. Diagn Interv Radiol 15:111–120

    PubMed  Google Scholar 

  44. Chopra S, Dodd GD III, Chintapalli KN, et al. (2001) Tumor recurrence after radiofrequency thermal ablation of hepatic tumors: spectrum of findings on dual-phase contrast-enhanced CT. AJR Am J Roentgenol 177:381–387

    PubMed  CAS  Google Scholar 

  45. Assumpcao L, Choti M, Pawlik TM, Gecshwind JF, Kamel IR (2009) Functional MR imaging as a new paradigm for image guidance. Abdom Imaging 34:675–685

    Article  PubMed  Google Scholar 

  46. Schraml C, Schwenzer NF, Clasen S, et al. (2009) Navigator respiratory-triggered diffusion-weighted imaging in the follow-up after hepatic radiofrequency ablation-initial results. J Magn Reson Imaging 29:1308–1316

    Article  PubMed  Google Scholar 

  47. Pupulim LF, Hakime A, Barrau V, et al. (2009) Fatty hepatocellular carcinoma: radiofrequency ablation–imaging findings. Radiology 250:940–948

    Article  PubMed  Google Scholar 

  48. Cho YK, Kim JK, Kim MY, Rhim H, Han JK (2009) Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 49:453–459

    Article  PubMed  Google Scholar 

  49. Sironi S, De Cobelli F, Livraghi T, et al. (1994) Small hepatocellular carcinoma treated with percutaneous ethanol injection: unenhanced and gadolinium-enhanced MR imaging follow-up. Radiology 192:407–412

    PubMed  CAS  Google Scholar 

  50. Ebara M, Kita K, Sugiura N, et al. (1995) Therapeutic effect of percutaneous ethanol injection on small hepatocellular carcinoma: evaluation with CT. Radiology 195:371–377

    PubMed  CAS  Google Scholar 

  51. Rimassa L, Santoro A (2009) Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther 9:739–745

    Article  PubMed  CAS  Google Scholar 

  52. Horger M, Lauer UM, Schraml C, et al. (2009) Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 9:208

    Article  PubMed  Google Scholar 

  53. Maksimovic O, Schraml C, Hartmann JT, et al. (2010) Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. AJR Am J Roentgenol 194:5–14

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Bonnie Hami, M.A. for her editorial assistance. This work was partly supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) (Grant No. 800-20100430).

Author information

Authors and Affiliations

  1. Department of Radiology, Seoul National University Hospital, 101 Daehangno, Jongno-gu, Seoul, 110-744, Korea

    Kyung Won Kim, Jeong Min Lee & Byung Ihn Choi

  2. Institute of Radiation Medicine, Seoul National University Hospital, 101 Daehangno, Jongno-gu, Seoul, 110-744, Korea

    Byung Ihn Choi

Authors
  1. Kyung Won Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeong Min Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Byung Ihn Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Byung Ihn Choi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, K.W., Lee, J.M. & Choi, B.I. Assessment of the treatment response of HCC. Abdom Imaging 36, 300–314 (2011). https://doi.org/10.1007/s00261-011-9683-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-011-9683-3

Keywords

Search

Navigation